News 19.03.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold an oral presentation outlining new preclinical...
News 17.03.2026 A new peer-reviewed report in the Journal of Burn Care & Research describes the compassionate use of denovoSkin™ in a pediatric patient with extensive burn injuries treated at Massachusetts General Hospital (Boston, USA). The publication details reconstructive procedures including contracture release and treatment of unstable scars, reporting high engraftment rates, durable...
News 13.03.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Zurich-Schlieren, Switzerland and Concord, Mass., March 12, 2026 – Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin...
Events, External events
Event date: 01.06.2026
📅 June 1–3, 2026
📍 ETH Zurich
Early Bird registration closes on 31 March 2026
If you are planning to attend, make sure to register before the deadline to benefit from the reduced early bird rate.
The Personalized Health Conference 2026 brings together researchers and experts from academia, clinics, and industry to discuss the...
News 10.03.2026 Schlieren (Zurich), Switzerland, March 10, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial and operational results for the full year 2025, marking another year of significant growth, increased market penetration, and strategic portfolio advancements. Total group revenue reached USD...